BIO at a glance
Bio-rad Laboratories Inc (BIO, SEC CIK 12208) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85.
- As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Bio-rad Laboratories Inc (BIO) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ENLOE COURTNEY C on November 10, 2026 of 902 shares at $386.17 per share.
- In the last 90 days, BIO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.2M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.6B
- +0.7% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$1.2M
- 13F holders
- 36 funds
- $2.6B · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added AI risk: generative AI may expose confidential information or generate infringing content amid evolving regulation
- Most material market update: aggressive pricing in multi-year public tenders, reducing annual tender opportunities and pressuring margins
- Regulatory risk: future LDT legislation could impose FDA-style requirements on customers using Bio-Rad life science products
- Operational risk: Middle East conflicts disrupting logistics, fuel costs and regional sales
- Financial risk: $1.2 billion debt, including $400 million due March 2027 and $800 million due March 2032
Management Discussion & Analysis
- Q3 revenue $656.4M, up 0.5% YoY from $653.0M, driven by Clinical Diagnostics
- Clinical Diagnostics revenue $401.8M, up 2.7% YoY; Life Science $254.6M, down 2.8%
- Gross margin 50.1% vs 52.6% YoY; SG&A margin 39.2% vs 31.7%
- Operating cash flow $303.2M vs $367.3M; cash, equivalents and short-term investments $1.66B
- Restructuring charges $77.6M; expected annual savings $30M to $35M by end-2027, with EMEA headwinds continuing
AI summary of the BIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.2: Item EX-99.2
- Q3 revenue $656M, up 0.5% reported and 0.7% currency-neutral, indicating modest top-line growth
- GAAP operating margin (7.6%), pressured by $77M restructuring and $50M intangible impairment charges
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 4, 2026
- Supplemental Earnings Presentation provides additional investor detail under Item 7.01
Item 7.01: Regulation FD Disclosure
- Supplemental earnings presentation covers Bio-Rad’s quarter ended September 30, 2026
- Investor-relevant financial detail is contained in Exhibit 99.2 and the company’s Investor Relations website
Item EX-99.1: Item EX-99.1
- Q3 revenue $656.4M, up 0.5% reported and 0.7% currency-neutral, signaling stabilization after prior declines
- Clinical Diagnostics revenue $401.8M, up 2.8% currency-neutral, offsetting Life Science’s 2.4% decline
Item 2.02: Results of Operations and Financial Condition
- Bio-Rad announced financial results for the quarter ended June 30, 2026
- Supplemental Earnings Presentation referenced under Item 7.01, with detailed results in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Supplemental earnings presentation covers Bio-Rad’s quarter ended June 30, 2026
- Materials available through Bio-Rad Investor Relations and Exhibit 99.2
Item 2.05: Costs Associated with Exit or Disposal Activities
- Strategy-driven restructuring initiated July 31, 2026, targeting global operations and functions
- Estimated pre-tax charges of approximately $80 million to $90 million, primarily termination benefits and severance
Item EX-99.1: Item EX-99.1
- Q2 revenue $651.0M, essentially flat year over year; currency-neutral revenue declined 1.9%
- Life Science revenue $252.0M, down 4.1% reported and 5.1% currency-neutral amid academic research weakness
AI summaries of BIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BIO
Don't miss the next BIO filing
- Alerts as it files. A push when BIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BIO, by share count.
- Ask anything. An AI agent that reads every BIO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ENLOE COURTNEY C | Sell | Nov 10, 2026 | 902 | $386.17 |
| BARRY JAMES | Sell | Nov 9, 2026 | 1,400 | $385.63 |
| DiVincenzo Jonathan P. | Sell | Nov 9, 2026 | 919 | $390.47 |
| DiVincenzo Jonathan P. | F | Oct 24, 2026 | 951 | $369.95 |
| DiVincenzo Jonathan P. | M | Oct 24, 2026 | 1,869 | - |
| DiVincenzo Jonathan P. | M | Oct 24, 2026 | 1,869 | - |
| EVRAN SEDAT | F | Oct 20, 2026 | 487 | $354.50 |
| EVRAN SEDAT | M | Oct 20, 2026 | 1,044 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.6B | $2.6B |
| Gross Profit | - | $1.4B | $1.3B |
| Operating Income | - | $269.0M | $47.2M |
| Net Income | - | -$1.8B | $759.9M |
| Gross Margin | - | 53.7% | 51.9% |
| Op. Margin | - | 10.5% | 1.8% |
| Net Margin | - | -71.9% | 29.4% |
| Balance Sheet | |||
| Total Assets | $12.3B | $9.4B | $10.6B |
| Equity | $8.7B | $6.6B | $7.5B |
| ROE | - | -28.1% | 10.2% |
| Per Share | |||
| EPS | - | $-65.36 | $27.85 |
| Cash Flow | |||
| Operating CF | - | $455.2M | $532.2M |
| CapEx | - | $165.6M | $157.6M |
Source: XBRL data in Bio-rad Laboratories Inc (BIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 36 | $2.63B |
| Q2 2026 | 36 | $2.09B |
| Q1 2026 | 37 | $1.96B |
| Q4 2025 | 33 | $2.01B |
| Q3 2025 | 34 | $1.94B |
| Q2 2025 | 31 | $1.71B |
| Q1 2025 | 29 | $1.33B |
| Q4 2024 | 28 | $1.57B |
- Morgan Stanley+116.9K (+61%)
- D.E. Shaw & Co+77.5K (+402%)
- BlackRock+41.4K (+2%)
- Millennium Management+35.5K (+59%)
- Raymond James Financial+10.0K (+27%)
- Goldman Sachs Group−152.7K (-84%)
- Dimensional Fund Advisors−58.6K (-6%)
- JPMorgan Chase & Co−52.1K (-51%)
- Bank of America Corp−51.7K (-11%)
- Wells Fargo & Co−46.9K (-48%)
- FMR LLC (Fidelity)−4.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 264 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 27, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | - | |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | May 13, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | - | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
BIO SEC filings: frequently asked questions
Are BIO insiders buying or selling?
In the last 90 days, Bio-rad Laboratories Inc (BIO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BIO stock?
As of September 30, 2026, the largest Bio-rad Laboratories Inc (BIO) holders among the 13F filers tracked by SignalX were BlackRock ($657.3 million), Dimensional Fund Advisors ($334.6 million), Vanguard Capital Management LLC ($312.4 million), Vanguard Portfolio Management LLC ($306.5 million), State Street Corp ($217.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85. The figures come from the XBRL data in the 10-K.
What did BIO report in its latest 8-K?
Bio-rad Laboratories Inc (BIO) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 revenue $656M, up 0.5% reported and 0.7% currency-neutral, indicating modest top-line growth.
What are the latest BIO SEC filings?
Bio-rad Laboratories Inc (BIO) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.
What is BIO's SEC CIK number?
Bio-rad Laboratories Inc (BIO)'s SEC Central Index Key (CIK) is 12208. EDGAR lists every BIO filing under that number.
Ask anything about BIO
The research agent reads BIO's filings, financials, insider trades and 13F holders, then answers with sources.